Efficacy and pharmacokinetics of lipid-based Amphotericin B formulations

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 4 SUPPL. 10, 2009, Pages 2-4

  Bellman, Romuald ^a  

^a Intensive Care Unit and Inflammation   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; ASPERGILLOSIS; CHILL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPOXIA; KIDNEY DYSFUNCTION; KIDNEY INJURY; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; RIGOR; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC MYCOSIS;

EID: 66749151024     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Utz JP, Treger A, McCullough NB, Emmons CW. Amphotericin B: intravenous use in 21 patients with systemic fungal diseases. Antibiot Annu. 1958-1959;6:628-634.
2. De Kruijff B, Demel RA. Polyene antibiotic-sterol interactions in membranes of Achole-plasma laidlawii cells and lecithin liposomes. 3. Molecular structure of the polyeneantibiotic-cholesterol complexes. Biochim Biophys Acta. 1974 26;339:57-70.
3. Baginski M, Resat H, McCammon JA. Molecular properties of amphotericin B membrane channel: a molecular dynamics simulation. Mol Pharmacol. 1997 52:560-570.
4. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev. 1996 9:512-531.
5. Barker KS, Rogers PD. Recent insights into the mechanisms of antifungal resistance. Curr Infect Dis Rep. 2006;8:449-456.
6. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol. 2008;46:97-112.
7. Enzon Pharmaceuticals Inc. Abelcet prescribing information. Available online: http://www.enzon.com/company/abelcet-feb-2009.pdf. Accessed February 1, 2009.
8. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A; L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155-1163.
9. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40:511-520.
10. Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112:1282-1287.
11. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-771.
12. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155-1163.
13. Astellas Pharma US Inc. Ambisome prescribing information. Available online: http://www.astellas.us/docs/Ambisome.pdf. Accessed February 1, 2009.
14. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997;24:635-642.
15. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296-302.
16. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359-366.
17. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol. 2007;2:37-58.
18. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995;39:2042-2047.
19. Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997;41:2201-2208.
20. Frothingham R. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis. 2002;35:896-897
21. Bellmann R, Egger P, Wiedermann CJ. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis. 2003;36:1500-1501.
22. Egger P, Bellmann R, Wiedermann CJ. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;760:307-313.
23. Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother. 2003;51: 671-681.
24. Bellmann R, Egger P, Djanani A, Wiedermann CJ. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int J Antimicrob Agents. 2004;23:80-83.
25. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989;33:362-368.
26. Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57:1153-1160.
27. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40:511-520.
28. Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112:1282-1287.
29. Weiler S, Bellmann-Weiler R, Joannidis M, Bellmann R. Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob Agents Chemother. 2007;51:4211-4213.
30. van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007; 59: 952-956.
31. Weiler S, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R. Levels of amphotericin B lipid formulations in ascites. J Antimicrob Chemother. 2008;62:1163-1164.
32. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother. 2006;50:3418-3423.
33. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28-S39.